PLGA nanoparticles for intravitreal peptide delivery: statistical optimization, characterization and toxicity evaluation

References

• Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007;4:371–388.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release 2014;193:100–112.
   PubMed Web of Science ®Google Scholar
• Kim YC, Chiang B, Wu X, Prausnitz MR. Ocular delivery of macromolecules. J Control Release 2014;190:172–181.
   PubMed Web of Science ®Google Scholar
• Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010;12:348–360.
   PubMed Web of Science ®Google Scholar
• Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev 1995;16:39–43.
   Web of Science ®Google Scholar
• Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006;58:1131–1135.
   PubMed Web of Science ®Google Scholar
• Rodríguez Ramírez M, del Barrio Manso MI, Martín Sánchez MD. Intravitreal injections: what do patients prefer? Analysis of patient's satisfaction and preferences about where to perform intravitreal injections. Arch Soc Esp Oftalmol (Eng Ed) 2014;89:477–483.
   PubMedGoogle Scholar
• Xu Q, Kambhampati S, Kannan R. Nanotechnology approaches for ocular drug delivery. Middle East Afr J Ophthalmol 2013;20:26–37.
   PubMedGoogle Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012;161:505–522.
   PubMed Web of Science ®Google Scholar
• Gupta H, Aqil M, Khar RK, et al. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 2010;6:324–333.
   PubMed Web of Science ®Google Scholar
• Al-Halafi AM. Nanocarriers of nanotechnology in retinal diseases. Saudi J Ophthalmol 2014;28:304–309.
   PubMedGoogle Scholar
• Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012;8:147–166.
   PubMed Web of Science ®Google Scholar
• Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 2010;29:596–609.
   PubMed Web of Science ®Google Scholar
• Chen YS, Green CR, Danesh-Meyer HV, Rupenthal ID. Neuroprotection in the treatment of glaucoma-A focus on connexin43 gap junction channel blockers. Eur J Pharm Biopharm 2015;95:182–193.
   PubMed Web of Science ®Google Scholar
• Danesh-Meyer HV, Zhang J, Acosta ML, et al. Connexin43 in retinal injury and disease. Prog Retin Eye Res 2016;51:41–68.
   PubMed Web of Science ®Google Scholar
• Clemente Z, Castro VLSS, Moura MAM, et al. Toxicity assessment of TiO2 nanoparticles in zebrafish embryos under different exposure conditions. Aquat Toxicol 2014;147:129–139.
   PubMed Web of Science ®Google Scholar
• Vibe CB, Fenaroli F, Pires D, et al. Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish. Nanotoxicology 2016;10:680–688.
   PubMed Web of Science ®Google Scholar
• Govender T, Stolnik S, Garnett MC, et al. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 1999;57:171–185.
   PubMed Web of Science ®Google Scholar
• Elmizadeh H, Khanmohammadi M, Ghasemi K, et al. Preparation and optimization of chitosan nanoparticles and magnetic chitosan nanoparticles as delivery systems using Box–Behnken statistical design. J Pharm Biomed Anal 2013;80:141–146.
   PubMed Web of Science ®Google Scholar
• Feczkó T, Tóth J, Dósa G, Gyenis J. Optimization of protein encapsulation in PLGA nanoparticles. Chem Eng Process 2011;50:757–765.
   Web of Science ®Google Scholar
• Huang J, Wigent RJ, Schwartz JB. Drug–polymer interaction and its significance on the physical stability of nifedipine amorphous dispersion in microparticles of an ammonio methacrylate copolymer and ethylcellulose binary blend. J Pharm Sci 2008;97:251–262.
   PubMed Web of Science ®Google Scholar
• Puttipipatkhachorn S, Nunthanid J, Yamamoto K, Peck GE. Drug physical state and drug-polymer interaction on drug release from chitosan matrix films. J Control Release 2001;75:143–153.
   PubMed Web of Science ®Google Scholar
• Sonam CH, Kumar V. Taguchi design for optimization and development of antibacterial drug-loaded PLGA nanoparticles. Int J Biol Macromol 2014;64:99–105.
   PubMed Web of Science ®Google Scholar
• Patel RR, Chaurasia S, Khan G, et al. Cromolyn sodium encapsulated PLGA nanoparticles: an attempt to improve intestinal permeation. Int J Biol Macromol 2016;83:249–258.
   PubMed Web of Science ®Google Scholar
• Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 2005;290:137–144.
   PubMed Web of Science ®Google Scholar
• Budhian A, Siegel SJ, Winey KI. Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J Microencapsul 2005;22:773–785.
   PubMed Web of Science ®Google Scholar
• Sharma D, Maheshwari D, Philip G, et al. Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using Box–Behnken design: in vitro and in vivo evaluation. Bio Med Res Int 2014;2014:156010.
   Google Scholar
• Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces 2005;44:65–73.
   PubMed Web of Science ®Google Scholar
• Hill AJ, Teraoka H, Heideman W, Peterson RE. Zebrafish as a model vertebrate for investigating chemical toxicity. Toxicol Sci 2005;86:6–19.
   PubMed Web of Science ®Google Scholar
• Rubinstein AL. Zebrafish assays for drug toxicity screening. Expert Opin Drug Metab Toxicol 2006;2:231–240.
   PubMed Web of Science ®Google Scholar
• McGrath P, Li CQ. Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discov Today 2008;13:394–401.
   PubMed Web of Science ®Google Scholar
• Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005;4:35–44.
   PubMed Web of Science ®Google Scholar
• Hu YL, Qi W, Han F, et al. Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model. Int J Nanomed 2011;6:3351–3359.
   PubMed Web of Science ®Google Scholar
• Asharani PV, Wu YL, Gong Z, Valiyaveettil S. Toxicity of silver nanoparticles in zebrafish models. Nanotechnology 2008;19:255102.
   PubMed Web of Science ®Google Scholar
• Usenko CY, Harper SL, Tanguay LR. In vivo evaluation of carbon fullerene toxicity using embryonic zebrafish. Carbon N Y 2007;45:1891–1898.
   PubMed Web of Science ®Google Scholar
• Kim TK, Zaikova T, Hutchison JE, Tanguay RL. Gold nanoparticles disrupt zebrafish eye development and pigmentation. Toxicol Sci 2013;133:275–288.
   PubMed Web of Science ®Google Scholar